Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Has files: YesSubject: search.filters.subject.streptozotocin

Search Results

Now showing 1 - 3 of 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Six week follow-up of metabolic effects induced by a high-fat diet and streptozotocin in a rodent model of type 2 diabetes mellitus
    (Macedonian Academy of Sciences and Arts, 2014)
    ;
    ;
    ;
    ;
    This study was initiated to refine and characterize a nongenetic experimental model of type 2 diabetes mellitus and to follow up various metabolic parameters up to six weeks after diabetes induction. Male Wistar rats were divided into 4 groups: CON group--consumed standard rat chow and served as control; HFD group--consumed high-fat diet (45% calories as fat); STZ group-was injected once intraperitoneally with streptozotocin (35 mg/kg) on day 14, and DM-2 group--consumed high-fat diet and was injected with streptozotocin. The metabolic parameters were measured one week after streptozotocin injection (week 3) and at the end of the study (week 9). Our results confirm that HFD-group developed dyslipidaemia, obesity and insulin resistance. All metabolic parameters remained largely unaltered in STZ-group during the study. Only the combination of high-fat diet and streptozotocin (DM-2 group) induced type 2 diabetes that was characterized with moderate hyperglycaemia, insulin resistance, hypertriglyceridaemia, elevated free fatty acids, hypercholesterolaemia and increased plasma glucagon levels at the time of diabetes onset (week 3). The observed changes of the metabolic parameters after six additional weeks demonstrated an aggravated diabetic state, as confirmed from significantly increased fasting plasma glucose values, insufficient insulin secretion, severe hyperlipidaemia, increased glucagon levels, decreased serum adiponectin concentrations and significantly elevated urinary protein excretion. These results indicate that apart from its utility as a model of diabetes aetiology, this model could also be used for elucidating the role of the hormones adiponectin and glucagon in the progression of type 2 diabetes, as well as for investigating the diabetic complications.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    NEPHROPROTECTIV EFFECTS OF CANDESARTAN ON DIABETIC NEPHROPATHY IN RATS
    (Macedonian Association of Anatomists and Morphologists, 2023)
    ;
    ;
    ;
    Kolovchevski, Nikola
    ;
    Shikole, Emilija
    Diabetic nephropathy (DN) stands out as a primary contributor to end-stage kidney damage. The renin-angiotensin system (RAS) plays a pivotal role in the advancement of DN, making angiotensin receptor blockers (ARBs) particularly noteworthy due to their influence on angiotensin II in DN development. This study investigated the impact of the angiotensin receptor blocker candesartan (CAN) on rats with streptozotocin (STZ)-induced DN, characterized by albuminuria, renal hypertrophy, and mild glomerulosclerosis.DN was induced in normotensive Wistar rats through a single injection of STZ (60 mg/kg ip). STZ administration led to diabetes mellitus (DM) symptoms and DN indicators, such as poor general condition, weight loss, increased kidney weight, elevated serum creatinine levels and BUN, augmented diuresis, and notable albuminuria. These manifestations were prominent at 4 weeks, intensifying further at 8 and 12 weeks post-STZ injection. Commencing candesartan treatment (5 mg/kg BW) at the 4-week mark post-STZ injection significantly alleviated all DN symptoms, reducing serum creatinine values and BUN, albuminuria, and diuresis. Histopathological examination at 8 and 12 weeks revealed that candesartan effectively mitigated glomerulopathy progression, improved the glomerulosclerotic index, and attenuated renal histological abnormalities induced by STZ. In conclusion, candesartan treatment ameliorates STZ-induced nephropathic changes in DM rats.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    The role of TGF-β1 in the development of diabetic nephropathy experimentally induced by Streptozotocin and the nephroprotective effects of Candesartan
    (Macedonian Association of Anatomists and Morphologists, 2023-12)
    ;
    ;
    Shikole Emilija
    ;
    Kolovchevski, Nikola
    ;
    Labachevski, Bojan
    Diabetic nephropathy (DN) stands as a prevalent and severe complication of diabetes mellitus (DM), lacking adequate medical therapy. The molecular mechanisms contributing to glomerular membrane damage involve the overactivity of angiotensin II, heightened expression of nephrin, vascular endothelial growth factor (VEGF), and notably, intraglomerular transforming growth factor TGF-β1. Pharmaceutical treatments targeting hemodynamic disturbances in diabetic nephropathy, such as ACE inhibitors and angiotensin receptor blockers (ARBs), hold promise for DN therapy. This study aimed to assess the role of intraglomerular TGF-β expression in experimentally induced DN in rats and explore the nephroprotective effects of candesartan. Diabetes mellitus was induced through a single intraperitoneal injection of streptozotocin (STZ) at 60 mg/kg, and DN was allowed to develop over four weeks. DM rats were randomly assigned to two groups: STZ (untreated) and STZ+CAN (treated with candesartan at 5 mg/kg/day from week 4 to week 12). STZ administration led to a substantial increase in TGF-β1 expression in the glomeruli, exceeding control levels by 5-6 times. Candesartan treatment demonstrated a significant reduction in glomerular proliferation and subsequent expansion of the mesangial matrix, suggesting a potential mechanism by which these drugs achieve therapeutic effects.